Patents by Inventor Steven Grant

Steven Grant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biopharmaceutical compositions comprising antibody variants
    Patent number: 11613571
    Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 28, 2023
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Chika Akinseye, Tejinder Bhinder, Li Cui, Steven Grant, Laura Hook, Alan Peter Lewis, Martin Anibal Orecchia
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20220315652
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: March 10, 2021
    Publication date: October 6, 2022
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L
    Publication number: 20220073636
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 10, 2022
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Antibody polypeptides that antagonize CD40L
    Patent number: 11180567
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 23, 2021
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40
    Patent number: 11136406
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 5, 2021
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
  • Anti P2Xreceptor antibodies and fragments thereof
    Patent number: 10988532
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 27, 2021
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • BIOPHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODY VARIANTS
    Publication number: 20210115128
    Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: May 21, 2019
    Publication date: April 22, 2021
    Inventors: Chika AKINSEYE, Tejinder BHINDER, Li CUI, Steven GRANT, Laura HOOK, Alan Peter LEWIS, Martin Anibal ORECCHIA
  • BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
    Publication number: 20210017269
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: August 7, 2020
    Publication date: January 21, 2021
    Inventors: Steven GRANT, Martin ORECCHIA, Chika AKINSEYE, Laura HOOK, Alan LEWIS, Tejinder BHINDER
  • Biopharmaceutical compositions and related methods
    Patent number: 10787509
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: September 29, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Steven Grant, Martin Orecchia, Chika Akinseye, Laura Hook, Alan Lewis, Tejinder Bhinder
  • METHODS OF TREATING IMMUNE DISEASES BY ADMINISTERING ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40
    Publication number: 20200199244
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
  • Body cooling assembly
    Patent number: 10619913
    Abstract: A body cooling assembly for cooling parts of a body includes a belt that is extendable around a waist. A housing is mounted on the belt includes a top wall, a bottom wall and a perimeter wall that extends between and is attached to the top and bottom wall. The housing has a first aperture and a second aperture for taking in and expelling air. A cooling unit is mounted in the housing. When actuated the cooling unit draws air into the housing, cools the air and dispends the cold air outwardly. A plurality of tubes is fluidly coupled to the housing and in thermal communication with the cooling unit such that air moves through the cooling unit and exits the housing through the tubes. The tubes are positionable on parts of a body and have a plurality of vent holes wherein each tube releases air.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: April 14, 2020
    Inventors: Michael Grant, Steven Grant, Sr.
  • Nucleic acids encoding antibody polypeptides that antagonize CD40
    Patent number: 10544228
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 28, 2020
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
  • ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L
    Publication number: 20190100595
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 4, 2019
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • BODY COOLING ASSEMBLY
    Publication number: 20190101322
    Abstract: A body cooling assembly for cooling parts of a body includes a belt that is extendable around a waist. A housing is mounted on the belt includes a top wall, a bottom wall and a perimeter wall that extends between and is attached to the top and bottom wall. The housing has a first aperture and a second aperture for taking in and expelling air. A cooling unit is mounted in the housing. When actuated the cooling unit draws air into the housing, cools the air and dispends the cold air outwardly. A plurality of tubes is fluidly coupled to the housing and in thermal communication with the cooling unit such that air moves through the cooling unit and exits the housing through the tubes. The tubes are positionable on parts of a body and have a plurality of vent holes wherein each tube releases air.
    Type: Application
    Filed: October 4, 2017
    Publication date: April 4, 2019
    Inventors: Michael Grant, Steven Grant, SR.
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20190040129
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: July 11, 2018
    Publication date: February 7, 2019
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L
    Patent number: 10196451
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 5, 2019
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
    Publication number: 20180340023
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: May 24, 2018
    Publication date: November 29, 2018
    Inventors: Steven Grant, Martin Orecchia, Chika Akinseye, Laura Hook, Alan Lewis, Tejinder Bhinder
  • Anti P2X7 receptor antibodies and fragments thereof
    Patent number: 10053508
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: August 21, 2018
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Variable retraction rate pump and method for operating same
    Patent number: 9982669
    Abstract: A pump system includes a pump and a storage volume in fluid communication with a discharge port of the pump. The pump includes a housing defining a pump bore and a pump piston disposed in sliding engagement with the pump bore, the pump piston being in selective fluid communication with the discharge port of the pump. A method for operating the pump system includes determining a time to drain an amount of a first fluid from the storage volume, and retracting the pump piston within the pump bore at a target retraction rate based at least partly on the time to drain the first fluid from the storage volume.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 29, 2018
    Assignee: Caterpillar Inc.
    Inventors: Paul Desiderio, Daniel Puckett, Steven Grant, Joshua Steffen
  • ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L
    Publication number: 20180051091
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: August 3, 2017
    Publication date: February 22, 2018
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW